Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Moderate Buy" from Analysts

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) has been assigned an average rating of "Moderate Buy" from the sixteen ratings firms that are presently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $53.40.

A number of equities research analysts have recently commented on KYMR shares. Morgan Stanley lifted their price objective on Kymera Therapeutics from $45.00 to $49.00 and gave the company an "equal weight" rating in a research report on Wednesday, November 6th. UBS Group cut their price target on Kymera Therapeutics from $80.00 to $74.00 and set a "buy" rating on the stock in a research note on Monday, November 4th. Wolfe Research upgraded Kymera Therapeutics from a "peer perform" rating to an "outperform" rating and set a $65.00 price objective on the stock in a research note on Monday, August 26th. Guggenheim upped their target price on Kymera Therapeutics from $45.00 to $52.00 and gave the company a "buy" rating in a report on Friday, November 1st. Finally, Leerink Partners reaffirmed an "outperform" rating and set a $60.00 price target on shares of Kymera Therapeutics in a research note on Monday, September 9th.

Kymera Therapeutics Stock Performance

Shares of NASDAQ:KYMR traded down $1.02 on Wednesday, hitting $45.89. 147,209 shares of the company's stock were exchanged, compared to its average volume of 582,932. The firm's 50-day moving average is $46.66 and its 200 day moving average is $42.43. The company has a market capitalization of $2.97 billion, a PE ratio of -20.05 and a beta of 2.16. Kymera Therapeutics has a 1-year low of $20.46 and a 1-year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.01. The business had revenue of $3.74 million during the quarter, compared to analysts' expectations of $10.34 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The company's quarterly revenue was down 20.9% compared to the same quarter last year. During the same period last year, the firm earned ($0.90) EPS. On average, analysts anticipate that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of the stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 15.82% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Kymera Therapeutics

Several hedge funds have recently made changes to their positions in KYMR. Massachusetts Financial Services Co. MA lifted its stake in Kymera Therapeutics by 11.7% during the third quarter. Massachusetts Financial Services Co. MA now owns 453,377 shares of the company's stock worth $21,458,000 after purchasing an additional 47,507 shares during the period. Bank of New York Mellon Corp lifted its stake in Kymera Therapeutics by 19.3% during the second quarter. Bank of New York Mellon Corp now owns 156,211 shares of the company's stock worth $4,663,000 after purchasing an additional 25,317 shares during the period. Renaissance Technologies LLC bought a new position in Kymera Therapeutics during the second quarter worth about $4,271,000. Eventide Asset Management LLC lifted its stake in Kymera Therapeutics by 9.9% during the third quarter. Eventide Asset Management LLC now owns 507,902 shares of the company's stock worth $24,039,000 after purchasing an additional 45,803 shares during the period. Finally, E Fund Management Co. Ltd. lifted its stake in Kymera Therapeutics by 391.2% during the second quarter. E Fund Management Co. Ltd. now owns 48,946 shares of the company's stock worth $1,461,000 after purchasing an additional 38,981 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.